Launched officially on December 2, China’s National Drug Price Registry now offers online and offline price filing and inquiry services for pharmaceutical firms at home and abroad.

The platform helps enterprises build global pricing frameworks and drives the worldwide commercialization of innovative medicines.

Pharmaceutical manufacturers may voluntarily file drug prices according to business demands. Registered prices are accepted locally, shared nationwide and disclosed globally. Marketing authorization holders can obtain multilingual inquiry certificates serving as official proof of price registration.

This official documentation delivers critical pricing credentials for companies expanding into international markets.

An official with the National Healthcare Security Administration (NHSA) stated that Chinese biopharma firms sealed over 103 out-licensing deals worth more than USD 92 billion in the first three quarters of 2025. Domestic end-market prices have become an increasingly vital global reference. Nevertheless, conventional fragmented pricing systems fail to meet diversified global expansion needs, leaving manufacturers troubled by incomplete pricing records and insufficient official certification when setting overseas prices.

“Overseas regulators usually demand market prices from launch territories for reference during market entry. We urgently need a formal price verification mechanism,” commented Fan Lin, Vice President of JW Therapeutics, echoing a widespread industry demand.

Drawing on international best practices, the globally accessible registry delivers authoritative, standardized and transparent price filing and inquiry services. It not only empowers Chinese pharmaceutical enterprises to go global but also attracts high-quality foreign new drugs to enter China, enabling two-way growth of “bringing in” and “going global”.

Nine domestic and international pharmaceutical enterprises, including Yifan Pharma, Roche, Hengrui Medicine and JW Therapeutics, completed the first batch of price registrations. The NHSA concurrently issued an Announcement on Launching Drug Price Filing and Inquiry Services, clarifying filing scope, procedures and service details.

Service Hall of China’s National Drug Price Registry (Photo provided by NHSA)

The launch of the registry constitutes a pivotal measure to boost the pharmaceutical industry.

China has rolled out a full-spectrum support system via 16 special policies for innovative drug development, and introduced the first commercial health insurance catalog for innovative medicines to open new market access channels. In recent years, coordinated policy and market measures have fostered a favorable ecosystem for pharmaceutical innovation.

The ultimate goal of innovative drug policies is to ensure accessible, affordable and timely medication for patients. Among the 91 drugs added to the 2024 National Reimbursement Drug List (NRDL), 33 were included within the same year of approval. The average interval between drug approval and NRDL inclusion has been shortened to roughly one year. Policy dividends are rapidly translated into tangible public health benefits, getting life-saving medicines to patients faster.

Balancing robust industrial growth and warm public healthcare security, China embraces opening-up to inject new momentum into the global pharmaceutical market and extend health benefits to populations worldwide.

Thank you for following the official platform of Vanworld! We are committed to providing you with professional, reliable and cutting-edge medical and health information.

Kind Reminder: All content released on this platform is for popular science of health knowledge only, intended to share more health-related information, and shall not replace professional medical diagnosis. Please be sure to consult a qualified doctor and strictly follow medical advice for specific diagnosis and treatment plans.

Disclaimer: Reposted from Xinhuanet for information exchange. Views belong to the original author only, not this platform. For copyright issues, contact us for timely revision or removal. Thanks for your support.